Skip to main content
Medical Reference · Condition Monograph

Porphyria Cutanea Tarda

만발성피부포르피린증

A skin disease in which blisters repeatedly form on sun-exposed areas due to abnormal porphyrin metabolism. It mainly appears in adulthood, and symptoms can be effectively controlled when triggering factors are managed as well.

History

Porphyria cutanea tarda (PCT) is the best-known form among the "porphyrias," characterized by recurrent blistering of the skin. As its name tarda, meaning "appearing late," suggests, unlike the congenital porphyrias that appear from childhood, its symptoms tend to begin mainly in adulthood. It was first observed as a distinctive skin disorder in which blisters form on the backs of the hands and the face exposed to sunlight and wounds are slow to heal, and at times it was understood as a grouping of conditions with mixed causes.

As research accumulated, it became increasingly clear that "the root of the skin problem lies in the liver." In other words, the explanation was established that when the process in the liver that makes "heme," the key component of hemoglobin in the blood, does not proceed smoothly, light-sensitive substances (porphyrins) increase, travel through the blood, and accumulate in the skin, and when the skin is then exposed to sunlight, blisters and erosions form. In addition, it is closer to actual clinical practice to understand this disease not as "a disease that persists once it develops," but as one that can switch on and off in response to triggers such as iron overload, alcohol use, hepatitis, and hormone exposure.

Treatment strategies have also shifted in line with this changing understanding. In the past, symptomatic treatment to protect wounds and prevent secondary infection was the mainstay, but now treatment that breaks the cycle of the disease by removing triggers and lowering the iron and porphyrins accumulated in the body has become the standard. Representative methods are phlebotomy (venesection), which lowers iron stores by drawing blood at regular intervals, and drug therapy such as low-dose hydroxychloroquine (HCQ), which helps porphyrins accumulated in the liver to be excreted. Recent studies note that, as treatment of hepatitis C virus (HCV) has become widespread, an approach that reduces both the risk of PCT recurrence and liver complications has become important.

Causes

The core cause of PCT is "intermediate substances accumulating because the process of making heme does not proceed smoothly." The central enzyme is uroporphyrinogen decarboxylase (UROD). If this enzyme does not work sufficiently in the liver, porphyrins can increase, and because porphyrins readily generate reactive oxygen species when exposed to light, they cause skin damage.

However, "reduced enzyme function" alone does not cause the disease in everyone. In practice, symptoms tend to appear when triggers are added on top of a predisposition (vulnerability). Triggers commonly raise oxidative stress in the liver, disrupt the balance of iron metabolism, or create an environment in the liver in which porphyrins readily accumulate.

Triggers that are frequently a problem clinically include iron overload (such as elevated ferritin), heavy drinking, smoking, estrogen exposure (oral contraceptives and hormone therapy), type 2 diabetes and metabolic syndrome, chronic liver disease such as hepatitis C virus (HCV), chronic kidney failure and dialysis, and exposure to certain chemicals (such as chlorinated hydrocarbons). Recent studies emphasize that these factors must be addressed both as "causes" and as "treatment targets" to reduce recurrence.

Genetic Epidemiology

It is more accurate to describe PCT not as a "genetic disease" but as a disease in which genetic vulnerability may be involved. Some people have a UROD gene variant and may start with enzyme activity that is inherently low (familial type), in which case symptoms may appear relatively more easily even in the same environment. However, many people with the familial type remain asymptomatic throughout life, so heredity means not "certain onset" but "the risk may rise further when triggers overlap."

Most patients belong to the sporadic type, in which no clear UROD variant is identified. In this case, the disease develops when an environment is created in which enzyme function is suppressed only in the liver, and at the center of this are iron overload and oxidative stress. Another important genetic axis is a constitution prone to iron overload. If a person has genetic variants associated with hereditary hemochromatosis (HH), iron may accumulate more readily in the liver, and this can act to increase the risk of PCT.

Recent studies regard these genetic factors as possible clues explaining "why some people develop the disease or relapse more easily," while at the same time emphasizing that management of lifestyle factors and comorbidities largely determines the actual risk.

General Epidemiology

PCT is relatively rare overall, but it is known to be the most common form among the porphyrias. The actual frequency varies greatly by region, and underdiagnosis is likely. This is because the symptoms can look like eczema, contact dermatitis, or "sun allergy," so the underlying disease is not revealed unless porphyrin testing is performed.

It generally develops in adults and tends to be diagnosed in age groups in which alcohol use, smoking, metabolic diseases, and chronic liver disease are likely to coexist. An epidemiologically important feature is that comorbidities are common. Abnormal liver function, fatty liver, and findings of iron overload are often found together, and hepatitis C virus (HCV) infection or human immunodeficiency virus (HIV) infection may also coexist.

Recent studies have discussed the possibility that the long-term risk of hepatocellular carcinoma (HCC) may increase in some patients, emphasizing that care should not end with the skin symptoms but should include management of liver health as well.

Pathogenesis

The pathogenesis can be summarized as "porphyrins increase in the liver and, in the skin, meet light and cause damage." First, if the UROD enzyme step in heme synthesis in the liver does not proceed smoothly, uroporphyrin-series substances cannot move on to the next step and are left behind. These substances are oxidized and accumulate as porphyrins, and some also travel through the blood to the skin.

When porphyrins accumulated in the skin receive the energy of sunlight (especially ultraviolet light), they readily generate reactive oxygen species and damage the surrounding tissue. As a result, blisters and erosions recur in areas that receive a lot of sunlight, such as the backs of the hands, the forearms, and the face. Another key link is iron. When a lot of iron accumulates in the liver, oxidative stress increases, and this environment can further suppress enzyme function and intensify porphyrin accumulation. Alcohol use, hepatitis, smoking, and metabolic diseases can increase this oxidative stress or disturb the balance of iron metabolism, strengthening the vicious cycle.

Recent studies describe PCT as an "iron-related hepatic metabolic disease" and conclude that this is why iron-lowering treatment is effective.

Symptoms

The representative symptoms are vesicles (blisters) and skin fragility in sun-exposed areas. In areas with a lot of exposure, such as the backs of the hands and the arms, the skin can easily peel or tear even with slight friction or minor trauma, resulting in wounds. Blisters repeatedly form over these areas, and because the blisters rupture easily, erosions and oozing remain. Healing tends to be slow, so with repetition, scars may remain or small bumps that look like millet seeds (milia) may form.

Hyperpigmentation, in which the skin darkens, may accompany the condition, and in some people the skin may become hard or thickened. An increase in or coarsening of facial hair may also be observed as a relatively characteristic change. In addition, as porphyrins are excreted in the urine, the urine may take on a reddish or brownish tint and give the impression that it "looks dark."

In most cases, unlike other porphyrias, severe acute neurological symptoms are not the main feature, but nonspecific symptoms such as fatigue may overlap because of coexisting liver disease or metabolic disease.

Signs

The key to the signs seen on examination is the combination of "sun exposure + blisters + delayed healing." On the backs of the hands, the forearms, and the face, traces of ruptured blisters, erosions, and crusts recur, and shallow scars and milia may be seen together. Fragility, in which the skin looks thin or is easily damaged, may also be noted.

In some people, hardening or thickening of the skin on the neck, fingers, or elsewhere may accompany the condition, and facial hypertrichosis may also be observed. Laboratory findings may include elevated liver enzymes and findings of iron overload such as elevated ferritin.

Recent studies emphasize that simultaneous evaluation of "skin findings + liver/iron abnormalities" reduces the risk of recurrence.

Screening

The goal of screening is to quickly assess the likelihood of PCT and, at the same time, to identify triggers. First, the history is reviewed for recurrent blisters in sun-exposed areas, alcohol use and smoking, estrogen use, iron supplement use, a history of liver disease, and risk factors for hepatitis.

For testing, it is practical to check liver function tests (LFT) and iron metabolism (ferritin, transferrin saturation) with basic blood tests. At the same time, evaluating metabolic status with tests for hepatitis C virus (HCV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV), as well as glycated hemoglobin (HbA1c), allows triggers to be organized systematically.

If skin symptoms are suspected, a urine porphyrin screening test is performed, and if it is positive, quantitative testing and differentiation of the type follow.

Diagnosis

The key to confirming the diagnosis is identifying the characteristic pattern of increased porphyrins in the urine and plasma (or stool). Typically, 24-hour urine porphyrin quantitative testing and plasma porphyrin testing are helpful. If necessary, stool porphyrin testing is added to distinguish PCT from other porphyrias.

When abdominal pain or neurological symptoms are prominent and acute porphyria must be ruled out, urine porphobilinogen (PBG) and urine delta-aminolevulinic acid (ALA) are evaluated together.

Skin biopsy is performed selectively when differentiation is needed, and rather than replacing confirmation on its own, it is interpreted together with porphyrin testing.

Treatment

Treatment consists of removing triggers, reducing iron and porphyrins, and protecting the skin. Removing triggers includes abstaining from or cutting down on alcohol, quitting smoking, stopping unnecessary iron supplements, stopping or replacing estrogen (where possible), managing metabolic diseases, and treating hepatitis.

The most widely used specific treatment is phlebotomy. Drawing blood at regular intervals to reduce iron stores decreases oxidative stress in the liver, and porphyrin accumulation decreases, so skin lesions may improve. As an alternative or complementary treatment, low-dose hydroxychloroquine (HCQ) or chloroquine (CQ) can be used to promote the excretion of porphyrins from the liver.

Recent studies have established that both treatment axes, phlebotomy and hydroxychloroquine, are effective, with an approach of choosing between them according to the patient's condition (iron overload, liver disease, drug intolerance/risk of side effects). The key to skin protection is physical barriers such as gloves, long sleeves, and hats, and blistered areas are managed with wound care and dressings focused on preventing infection.

Prognosis

PCT is a disease with a high likelihood of improvement when it is properly diagnosed and treated. When triggers are reduced and iron-lowering treatment is carried out, blister formation decreases, skin fragility improves, and laboratory values often gradually normalize.

However, the most important variable in prognosis is recurrence. If resumed drinking, persistent iron overload, re-exposure to estrogen, uncontrolled metabolic disease, or untreated hepatitis remain, the condition may worsen again. In addition, in some patients liver fibrosis may accompany the disease, or the risk of liver complications may increase as hepatitis and iron overload overlap.

Recent studies have discussed an increased risk of hepatocellular carcinoma (HCC) in some patients and conclude that liver follow-up should be considered according to individual risk.

Prevention

Prevention is essentially lifestyle and medical management that reduces onset and recurrence. Abstaining from or cutting down on alcohol and quitting smoking lower oxidative stress in the liver and reduce the risk of recurrence. Avoid taking iron supplements on your own, and if ferritin is high, evaluate the cause and manage it together with your medical team. If you are at risk for hepatitis C virus (HCV), get tested and, if necessary, treated to reduce the burden on the liver. It is also important to manage obesity, high blood sugar, and dyslipidemia to reduce fatty liver and inflammation.

Finally, habits that reduce sun exposure directly help prevent skin symptoms. Physical barriers such as gloves, long sleeves, and hats are the basis, and if blisters form, early wound care reduces infection and scarring.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.